Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Sub-Study 3 of A Phase 1b/2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases (ES108001)

NCT07614477 is registered in ClinicalTrials.gov with Everest Medicines (China) Co.,Ltd. as lead sponsor.

NCT NCT07614477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07614477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Sub-Study 3 of A Phase 1b/2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases (ES108001)
Lead sponsor
Everest Medicines (China) Co.,Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
May 20, 2026
Completion date
March 31, 2029
Enrollment
45 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis (fsgs), iga nephropathy (igan), minimal change disease (mcd)